I did a comparision of the two trials in a different thread which ill copy below:
Lets do a comparison of Ruxolitnib vs Remestemcel-L trials:
Trial:Day 28 ORR:
- Single arm open label 49 patients
- Single arm open label 54 patients (Study 001)
Day 180 Survival:
- 40.7%-44.4% on grade 3-4 (grade c-d)
- 61%-67% on grade 3-4 (grade c-d)
Safety:
- 51% (n=25)
- 69% (n=37)
FDA Decision
- Multiple safety concerns/side effects including infections, sepsis, uti's, thrombosis and animia (adverse events lead to 31% of patients discontinuing treatment)
- No safety concerns identified with a safety profile similar to placebo (adverse events lead to 15% of patients discontinuing treatment)
- Approved
- ODAC voted 9-1 in favour of efficacy however FDA issued a CRL recommending a further trial to establish efficacy and to provide more scientific rationale to demonstrate potency relationships
Ruxolitnib has had a previous trial for the treatment of myelofibrosis. The trial results clearly show that from the available data, Remestemcel-L is a superior treatment with a much better safety profile.
Could msb argue that if the COVID-19 trial is successful this would provide sufficient evidence of relevant efficacy and safety similar to Ruxolitnib extension from myelofibrosis to GvHD based on the 1 single arm trial above?
- Forums
- ASX - By Stock
- MSB
- Ruxolitinib vs Ryoncil
Ruxolitinib vs Ryoncil, page-3
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B |
Open | High | Low | Value | Volume |
99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 99.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
99.5¢ | 18069 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 0.990 |
2 | 32880 | 0.985 |
7 | 256748 | 0.980 |
3 | 27201 | 0.975 |
8 | 170032 | 0.970 |
Price($) | Vol. | No. |
---|---|---|
0.995 | 18069 | 3 |
1.000 | 26186 | 7 |
1.005 | 72373 | 3 |
1.010 | 82743 | 7 |
1.015 | 72242 | 5 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online